mitochondrial ribosomal protein L35Genealiases: L35mt · MRP-L35 · bL35m
Q-omics provides the consensus-scored MRPL35 profile across patient tissues and cancer cell-line models. MRPL35 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MRPL35 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, MRPL35 RNA expression shows 19,782 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, COAD, and LSCC as cancer lineages where MRPL35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL35 survival associations across molecular data types. MRPL35 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL35 RNA expression–survival associations across cancer types. High MRPL35 expression shows unfavorable associations in UVM, ACC, LUAD, LIHC and HNSC, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MRPL35 RNA expression.
This table summarizes MRPL35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MRPL35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL35 shows lower tumor expression in COAD and KIRC and higher tumor expression in LIHC, LUSC, LUAD and BRCA. The COAD box plot shows higher MRPL35 RNA expression in normal versus tumor tissue (log2 FC = −0.690, t-test p < 0.001).
This table shows molecular features associated with MRPL35 in patient tissues and cancer cell lines. In patient samples, MRPL35 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL35 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
